Abstract
We report the use of estrone (E1)-based compounds in the search for inhibitors of 17β-hydroxysteroid dehydrogenase, in particular, type 3 (17β-HSD3). Results suggest that the compounds are good inhibitors of 17β-HSD3 and a number were found to be equipotent to the standard inhibitors used within the current study.
Keywords: 17β-Hydroxysteroid dehydrogenase, Type 3, Inhibition, Enzyme, Steroid-based compound, Prostate cancer, Estrone, Potential Inhibitors, Estrone (E1)-based compounds, Type 3 (17bHSD3), Standard inhibitors, Biochemical target, Androgen-dependent cancer, Breast cancer, Ester-based derivatives, Non-radioactive steroids, Perkin-Elmer Fourier Transform Paragon, PET polyester, 17b-Hydroxysteroid dehydrogenase, Inhibitory activity, Cycloalkyl based compounds
Letters in Drug Design & Discovery
Title: Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Volume: 7 Issue: 9
Author(s): Moniola S. Olusanjo and Sabbir Ahmed
Affiliation:
Keywords: 17β-Hydroxysteroid dehydrogenase, Type 3, Inhibition, Enzyme, Steroid-based compound, Prostate cancer, Estrone, Potential Inhibitors, Estrone (E1)-based compounds, Type 3 (17bHSD3), Standard inhibitors, Biochemical target, Androgen-dependent cancer, Breast cancer, Ester-based derivatives, Non-radioactive steroids, Perkin-Elmer Fourier Transform Paragon, PET polyester, 17b-Hydroxysteroid dehydrogenase, Inhibitory activity, Cycloalkyl based compounds
Abstract: We report the use of estrone (E1)-based compounds in the search for inhibitors of 17β-hydroxysteroid dehydrogenase, in particular, type 3 (17β-HSD3). Results suggest that the compounds are good inhibitors of 17β-HSD3 and a number were found to be equipotent to the standard inhibitors used within the current study.
Export Options
About this article
Cite this article as:
S. Olusanjo Moniola and Ahmed Sabbir, Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer, Letters in Drug Design & Discovery 2010; 7 (9) . https://dx.doi.org/10.2174/157018010792929496
DOI https://dx.doi.org/10.2174/157018010792929496 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Current Pharmaceutical Design Molecular Mechanisms and Potential Treatment Targets for Ovarian Cancer by Analyzing Transcriptional Regulatory Network
Letters in Drug Design & Discovery Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway
Anti-Cancer Agents in Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Do Drugs Work for ΟΑΒ Following Prostate Cancer Surgery
Current Drug Targets The Role of Aromatase Enzyme in Hormone Related Diseases and Plant- Based Aromatase Inhibitors as Therapeutic Regimens
Current Topics in Medicinal Chemistry Notch Signaling in Cardiovascular Disease and Calcification
Current Cardiology Reviews In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Relationships between Serotoninergic System and Skin Fibrotic
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results
Reviews on Recent Clinical Trials The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy
Current Drug Metabolism NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets Strain-Promoted Cycloadditions for Development of Copper-Free Click Reactions
Current Organic Chemistry Editorial [Hot Topic: The Application of Systems Biology and Bioinformatics Methods in Proteomics, Transcriptomics and Metabolomics (Guest Editor: Yu-Dong Cai)]
Protein & Peptide Letters Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry